Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the Half Year ended 30th September 2026. (Q2 FY27).

Date: 05.11.2026 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, ISIN: INE0MKA01014 Mumbai – 400001. SUB: EARNINGS PRESENTATION‐Q2 FY27. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the Half Year ended 30th September 2026. (Q2 FY27). Kindly take the above on record. Thanking You, Yours Faithfully For TRIDENT LIFELINE LIMITED SHRAVAN H PATEL MANAGING DIRECTOR DIN: 08629141 Encl: As Above Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India. Investor Presentation Trident Lifeline Limited (TLL) Q2 FY27 EARNINGS UPDATE Inside this presentation 03 08 11 19 20 Earnings About Our right Investment Financial update us to win rationale overview 03 | EARNINGS UPDATES Executive summary – Q2 FY27 (based on standalone financials) Revenue and profitability Return and capital Client and people Revenue from operations Return on equity (ROE) Manpower 210 bps 21% ₹32.7 crores 19% 24.1% 103 YoY growth YoY growth YoY growth Operating profit (EBITDA1) Return on capital employed Number of countries served 53% (ROCE) 287 bps 104% ₹9.8 crores 47 27.9% YoY growth YoY growth YoY growth EBITDA margin Number of global registrations2 Net debt to equity VS 653 bps 0.2x 6% 29.8% 0.3x 1,128 YoY growth in FY26 YoY growth Current ratio Profit after tax (PAT) VS Registrations filed 33% 2.1x ₹6.6 crores 2.8x 2,582 8% YoY growth in FY26 YoY growth 1: EBITDA: Earnings before interest, taxes, depreciation and amortization | 2: Excluding India 04 | EARNINGS UPDATES Executive summary – Q2 FY27 (based on consolidated financials) Revenue and profitability Return and capital Client and people Revenue from operations Return on equity (ROE) R&D and F&D investment2 267 bps 89% ₹47.1 crores 50% 24.9% ₹0.7 crores YoY growth YoY growth YoY growth Operating profit (EBITDA1) Return on capital employed Capacity utilization vs 65% (ROCE) 185 bps 32% ₹11.3 crores 46% 19.4% YoY growth YoY growth in Q2 FY26 EBITDA margin Net debt to equity VS Number of clients vs 217 bps 0.7x 31% 24.1% 0.7x 64 YoY growth YoY growth YoY growth Current ratio Profit after tax (PAT) Product Portfolio vs ₹6.6 crores 30% 1.8x 1.6x 3,710 3,625 YoY growth in FY26 in FY26 1: EBITDA: Earnings before interest, taxes, depreciation and amortization | 2. Figures as of H1 FY27 05 | EARNINGS UPDATES Performance update and management commentary Management commentary Our vision has always extended beyond strengthening our core pharmaceutical formulations business. We believe that developing complementary businesses will create additional avenues for growth and enable us to build a more diversified healthcare platform with the potential to create long-term value. Guided by this vision, over the past decade we have consistently invested in manufacturing capabilities, regulatory approvals, infrastructure and new business verticals. These investments have laid the foundation for our current growth trajectory, and as our businesses scale and operational capabilities strengthen, we are beginning to realize the potential of the platform we have built. As we enter the next phase, our priority is to translate these capabilities into sustained business growth. This will require continued focus on execution, expanding our market presence, strengthening our product portfolio and improving operational efficiencies. As our newer business verticals progress beyond their initial development and incubation stages, we expect their contribution to our consolidated performance to increase meaningfully over time. Hardik Desai, Chairman Looking ahead, our aspiration remains to triple our consolidated business over the next three years. Achieving this ambition will depend on our ability to scale our business verticals successfully, execute our plans with discipline and allocate capital prudently. We remain committed to pursuing sustainable growth while creating enduring value for our shareholders over the long term. 06 | EARNINGS UPDATES Performance update and management commentary Management commentary Q2 FY27 has been encouraging for Trident Lifeline Limited, reflecting strong business growth, improved profitability, and continued progress towards our long-term strategic objectives. Our performance is supported by progress in product registrations, expansion into new markets, additions to our product portfolio, contributions from subsidiaries, and improving utilisation of our existing manufacturing capacities. We are also progressing with the commissioning of our parenterals facility, which is expected to be commissioned after Diwali, subject to operational readiness. This will strengthen our manufacturing capabilities and support our future growth plans. The proposed preferential issue will further strengthen our financial resources. The proceeds will support the Company’s strategic priorities and provide a foundation for the next phase of expansion. During the H2 FY27, our focus will remain on improving capacity utilisation, accelerating execution, expanding our product and market presence, strengthening subsidiary performance, and maintaining financial discipline. Looking ahead, we remain committed to our ambition of tripling our consolidated business over the next three Ashish Bafna, Executive Director and CFO years. With our expanding platform, stronger execution capabilities, and disciplined approach to growth, we believe Trident Lifeline is well positioned to create sustainable long-term value for its shareholders. 07 | EARNINGS UPDATES Revenue split across segments – Q2 FY27 (based on consolidated financials) Others1 Tablets Capsules Medical Devices 11% -19% 183% 147% 6.8 17.0 17.2 15.5 3.0 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Total Revenue contribution (%) 47.1 16% Tablets 37% Capsules 31.3 19% Q2 FY26 50% Q2 FY27 Others Tablets Q2 FY26 Q2 FY27 1: Others include syrups, suspensions, dry powder bottles, ointments 08 | ABOUT US: COMPANY OVERVIEW Building a global healthcare platform The integrated trident ecosystem Trident at a glance Building a diversified manufacturing platform across formulations and medical devices ▪ Established in 2014 as an export-focused pharmaceutical company, building a scalable global healthcare platform Oral solids Liquids ▪ Diversified portfolio spanning pharmaceuticals, nutraceuticals, (Tablets / Capsules) (Syrups, Solutions) herbals, injectables, personal care, and medical devices ▪ Hybrid manufacturing model combining strategic partnerships with integrated manufacturing capabilities to enhance scalability Dry powder Ointments and sachets and topicals and supply reliability Platform ▪ Integrated WHO-GMP compliant manufacturing platform with scalable capabilities across oral solids, injectables, liquids, and Injectables Medical devices medical devices (Vials, Ampules) and surgical 5 10+ 80 crs. 46% 4 47.1 crs. 24.1% Business Years of Intrinsic value Capacity Manufacturing Q2 FY27 Q2 FY27 verticals experience of registrations utilization facilities revenue EBITDA margin We partner with distributors for market access while serving as their dedicated manufacturing and supply partner 09 | ABOUT US: OUR BUSINESS MODEL An integrated model creating value across the pharmaceutical value chain N Our operational excellence and H strategic enablers create a Procurement Manufacturing Exports self-reinforcing cycle of growth A Consolidated manufacturing L ▪ Trusted indigenous ▪ WHO-GMP compliant ▪ Strong presence across capacity (in million) / month1 N sourcing ensuring manufacturing with regulated and emerging I quality and cost scalable operations markets T Tablets 120 efficiency Capsules 120 E Dry powder bottles 3 [Showing first 8,000 characters — download PDF for full document]